BMS-986484 + nivolumab + oxaliplatin + capecitabine + fluorouracil + calcium folinate

This is an investigational **combination regimen** comprising BMS-986484 (a novel biologic therapy from Bristol Myers Squibb, precise target undisclosed as of September 2025), **nivolumab** (a programmed death-1 [PD-1] immune checkpoint inhibitor), **oxaliplatin** (a platinum-based chemotherapy), **capecitabine** (an oral prodrug of fluorouracil), **fluorouracil** (5-FU, a pyrimidine analog chemotherapy), and **calcium folinate** (leucovorin, used to enhance 5-FU cytotoxicity). - BMS-986484 is being evaluated for safety and tolerability, primarily in advanced/metastatic solid tumors including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction adenocarcinoma, and squamous cell carcinoma of the head and neck. - Nivolumab modulates immune response by blocking PD-1-mediated immune checkpoint inhibition. - Oxaliplatin, capecitabine/fluorouracil, and calcium folinate form a chemotherapeutic backbone commonly used in gastrointestinal cancer therapy. The combination is currently under phase 1 evaluation for advanced solid tumors[1][2][3][4][6].

Other names

5-fluorouracilleucovorin